Vice President, Laboratory Director
Dr. Dongbin Xu is board certified by the American Board of Medical Genetics and Genomics in Clinical Cytogenetics. Dr. Xu obtained his Master’s degree in genetics from Fudan University, Shanghai, China, in 2003. He then came to the United States in 2003 and earned his doctorate degree in biomedical science from the University of Texas M.D. Anderson Cancer Center at Houston in 2009. Two years later, he completed a fellowship in clinical cytogenetics at The Children’s Hospital of Philadelphia.
In 2012, Dr. Xu joined Shodair Children’s Hospital as the Director of Genetics Laboratory. Dr. Xu expanded multiple FISH testing panels for Leukemia and Lymphomas and initiated a clinical exome sequencing project using next-generation sequencing while he was managing the Shodair Genetics Laboratory to perform routine cytogenetic, SNP microarray, molecular genetic testing for inheritable genetic disorders, and hemato-oncology diseases. He is the author of dozens of articles regarding programmed cell death, cohesion-related human genetic disorders, disease modeling using stem cells, and diseases caused by chromosomal abnormalities. Dr. Xu joined HematoLogics as the Director of Clinical Cytogenetics in 2015 and became the Laboratory Director and the CLIA license holder for HematoLogics in 2021.
Dr. Xu is a fellow of the American College of Medical Genetics and Genomics. His area of specialty is cytogenetics, molecular cytogenetics (FISH), SNP microarray, and clinical molecular genetics, including next-generation sequencing.
Short version:
Dr. Dongbin Xu is board certified by the American Board of Medical Genetics and Genomics in Clinical Cytogenetics and a fellow of the American College of Medical Genetics and Genomics.
Dr. Xu joined HematoLogics as the Director of Clinical Cytogenetics in 2015 and became the Laboratory Director and the CLIA license holder for HematoLogics in 2021. His area of specialty is cytogenetics, molecular cytogenetics (FISH), SNP microarray, and clinical molecular genetics, including next-generation sequencing.
